Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancer

This publication has 31 references indexed in Scilit:

• Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
  Clinical Cancer Research, 2014
• Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck
  Head & Neck, 2013
• Cabozantinib in Progressive Medullary Thyroid Cancer
  Journal of Clinical Oncology, 2013
• Lactate Engages Receptor Tyrosine Kinases Axl, Tie2, and Vascular Endothelial Growth Factor Receptor 2 to Activate Phosphoinositide 3-Kinase/Akt and Promote Angiogenesis
  Journal of Biological Chemistry, 2013
• A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC
  Annals of Oncology, 2011
• Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review
  The Lancet Oncology, 2011
• Adverse effects of anticancer agents that target the VEGF pathway
  Nature Reviews Clinical Oncology, 2009
• Late recurrence from salivary gland cancer
  Cancer, 2007
• c-Met is essential for wound healing in the skin
  Journal of Cell Biology, 2007
• Expressions of Nuclear Factor κB, Inducible Nitric Oxide Synthase, and Vascular Endothelial Growth Factor in Adenoid Cystic Carcinoma of Salivary Glands: Correlations with the Angiogenesis and Clinical Outcome
  Clinical Cancer Research, 2005